Beta Adrenergic Agonists With Peripheral β-Blockade for Cognitive Gain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for diseases associated with adrenergic receptors, such as neurodegenerative disorders, lack effective compounds that can modulate these receptors and improve cognitive functions without causing adverse peripheral effects.
Innovation Solution
Development of beta adrenergic agonists and antagonists, including compounds according to specific formulas, which can selectively modulate adrenergic receptors, cross the blood-brain barrier, and minimize peripheral side effects by using peripherally acting β-blockers to inhibit peripheral receptor agonism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If beta adrenergic agonists are administered to treat neurodegenerative disorders and improve cognitive functions, then cognitive improvement is achieved, but peripheral side effects such as cardiac and metabolic effects occur
Solution Approach 1:
The invention divides the therapeutic effect into two separate components: a beta adrenergic agonist for central nervous system effects (cognitive improvement) and a peripherally acting beta-blocker for blocking peripheral effects. This segmentation allows the agonist to cross the blood-brain barrier and exert cognitive benefits while the peripherally acting beta-blocker selectively blocks peripheral beta receptors, preventing cardiac and metabolic side effects. The combination therapy achieves spatial separation of therapeutic and adverse effects.
Solution Approach 2:
The peripherally acting beta-blocker serves as an intermediary agent that selectively blocks beta adrenergic receptors in peripheral tissues (heart, lungs, metabolism) while allowing the beta adrenergic agonist to act on central nervous system receptors. This intermediary blocks the harmful peripheral transmission of the agonist's effects while preserving the desired central cognitive benefits.
2Reliability
If existing adrenergic receptor modulating compounds are used, then treatment of neurodegenerative disorders is attempted, but effective compounds that can modulate receptors without causing adverse peripheral effects are lacking
Solution Approach 1:
The invention merges two pharmacological agents with opposite but complementary actions: a beta adrenergic agonist that provides cognitive benefits by stimulating central beta receptors, and a peripherally acting beta-blocker that eliminates adverse effects by blocking peripheral beta receptors. This combination merges the therapeutic benefits of agonism with the safety profile of antagonism in peripheral tissues, creating a therapy that was previously unachievable with single compounds.
Data Source
AI summary
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.